Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2016 · 10-Q
Revenue$51.63M$51.63M+44.7% vs Q2 2015 Net Income$10.25M$10.25M+320.6% vs Q2 2015 EPS Diluted$0.18$0.18+350.0% vs Q2 2015 Operating Income$11,645,000+202.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$16,153,000+14.7% Margins · derivedOperating margin22.6%+11.8 pt vs Q2 2015
Net margin19.9%+13.0 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 5, 2016 · 36 d after period end